The major polycyclic aromatic hydrocarbon inducible-cy-tochrome P4501A1 gene (CYP1A1)
is presumed to be important in pulmonary carcinogenesis and toxicology because its …

Changes in phase II drug-metabolizing enzyme expression during development, as well as
the balance between phase I and phase II enzymes, can significantly alter the …

Although some patterns are beginning to emerge, our knowledge of human phase I drug-metabolizing
enzyme developmental expression remains far from complete. Expression has …

The human cytochrome P4503A forms show expression patterns subject to developmental
influence. CYP3A7 and CYP3A4 are generally classified as the major fetal and adult liver …

Profound changes in drug metabolizing enzyme (DME) expression occurs during development
that impacts the risk of adverse drug events in the fetus and child. A review of our current …

The CYP2C subfamily is responsible for metabolizing many important drugs and accounts
for about 20% of the cytochrome P450 in adult liver. To determine developmental expression …

The flavin-containing monooxygenases (FMOs) are important for the metabolism of numerous
therapeutics and toxicants. Six mammalian FMO genes (FMO1–6) have been identified, …

Significant changes in drug‐metabolizing enzyme (DME) expression occur during ontogeny.
Such changes can have a profound effect on therapeutic efficacy in the fetus and child, as …

… microsomes from samples spanning fetal (n = 73, 8–37 weeks) and postnatal (n = 165, 1 day…
Among subjects of known gestational and postnatal age (n = 29) increasing protein content …

Within the human cytochrome P450 family, specific forms show developmental expression
patterns that can affect drug clearance, efficacy, and safety. The objective of this study was to …